PubMed Journals Articles About "Perspectives Nanotechnology Management Gliomas" RSS

10:03 EST 18th December 2018 | BioPortfolio

Perspectives Nanotechnology Management Gliomas PubMed articles on BioPortfolio. Our PubMed references draw on over 21 million records from the medical literature. Here you can see the latest Perspectives Nanotechnology Management Gliomas articles that have been published worldwide.

More Information about "Perspectives Nanotechnology Management Gliomas" on BioPortfolio

We have published hundreds of Perspectives Nanotechnology Management Gliomas news stories on BioPortfolio along with dozens of Perspectives Nanotechnology Management Gliomas Clinical Trials and PubMed Articles about Perspectives Nanotechnology Management Gliomas for you to read. In addition to the medical data, news and clinical trials, BioPortfolio also has a large collection of Perspectives Nanotechnology Management Gliomas Companies in our database. You can also find out about relevant Perspectives Nanotechnology Management Gliomas Drugs and Medications on this site too.

Showing "Perspectives Nanotechnology Management Gliomas" PubMed Articles 1–25 of 11,000+

Perspectives of Nanotechnology in the Management of Gliomas.

Significant advances in the design and understanding of the materials and systems of 1-100 nm have provided unprecedented tools to probe, diagnose, and treat diseases at the molecular level with greater efficiency and accuracy. In particular, optical and chemical properties of nanomaterials are being exploited to improve the effectiveness of neuro-oncological and neurosurgical interventions. Modern nanotechnology-driven clinical applications may have significant impact on management of brain tumors.

Molecular classification of adult gliomas: recent advances and future perspectives.

This review summarizes recent advances in the molecular classification of adult gliomas.

Perspectives of immunotherapy in isocitrate dehydrogenase-mutant gliomas.

The present review introduces recent progress in eliciting the role of mutant isocitrate dehydrogenase (IDH) in gliomas, especially regarding its mode of action as a modulator of antitumor immune response, and provides rationales for targeting mutant IDH in glioma immunotherapy. Both the development of small molecule inhibitors repressing the enzymatic activity of mutant IDH and novel, mechanism-led combination immunotherapies are discussed.

Fluorescence-guided surgery with aminolevulinic acid for low-grade gliomas.

Fluorescence guided surgery has developed over the last 2 decades as a formidable augmentation strategy to promote maximal safe resection and diagnostic accuracy within gliomas. The majority of the literature evidence supporting this modality utilizes 5-aminolevulinic acid in the setting of high-grade gliomas. The role for fluorescence guided surgery in low-grade gliomas is less well defined.

Nanotechnology and multipotent adult progenitor cells in Reparative Medicine: therapeutic perspectives.

The biology of stem cells is one of the most dynamic and promising fields of the biological sciences, since it is the basis for the development of organisms. Its biological complexity demands efforts from several lines of research aimed mainly at its therapeutic use. Nanotechnology has been emerging as a new field of study, which shows great potential in the treatment of various diseases. This new area of health has been called "Nanomedicine" or "Bionanotechnology", which can be applied in Medicine by trans...

Diffuse Gliomas for Nonneuropathologists: The New Integrated Molecular Diagnostics.

Diffuse gliomas comprise the bulk of "brain cancer" in adults. The recent update to the 4th edition of the World Health Organization's classification of tumors of the central nervous system reflects an unprecedented change in the landscape of the diagnosis and management of diffuse gliomas that will affect all those involved in the management and care of patients. Of the recently discovered gene alterations, mutations in the Krebs cycle enzymes isocitrate dehydrogenases (IDHs) 1 and 2 have fundamentally cha...

Targeted Local Therapy for Management of Intracranial High-Grade Gliomas.

Systemic chemotherapy of malignant brain tumors has failed to achieve sufficient drug concentrations at the neoplasm site and frequently results in severe toxicities. Therefore, the local application of several anticancer agents, oncolytic viruses and vectors for gene therapy, immune-modifying preparations, and angiogenesis inhibitors has been investigated widely. Various modes of their administration were introduced, including intratumoral injections, implantation of reservoirs or pumps, convection-enhance...

Features of diffuse gliomas that are misdiagnosed on initial neuroimaging: a case control study.

The neuroimaging diagnosis of diffuse gliomas can be challenging owing to their variable clinical and radiologic presentation. The purpose of this study was to identify factors that are associated with imaging errors in the diagnosis of diffuse gliomas.

Photodynamic Therapy of Malignant Gliomas.

Recently, the clinical applications of photodynamic therapy (PDT) in the management of malignant brain tumors have attracted significant attention. Meta-analysis of the observational studies on this treatment in high-grade gliomas (Eljamel, 2010) included more than 1,000 patients and reported median survival in cases of newly diagnosed and recurrent glioblastoma multiforme (GBM) of 16.1 and 10.3 months, respectively. In some series, increase in the long-term survival rates was also observed. Few controlled ...

Radiation-Induced Gliomas.

Radiation therapy has been a cornerstone of cancer management for many decades and is an integral part of the multi-modality care of patients with brain tumors. The known serious side effects of radiation therapy on the head or central nervous system are uncommon and include radiation necrosis, microangiopathy, and progressive leukencephalopathy. In addition, there have been descriptions of radiation-induced tumors including sarcomas, gliomas, lymphomas, and carcinomas of the thyroid. Patients who have rece...

Comparison of adjuvant radiation therapy alone and chemotherapy alone for low-grade gliomas without surgical resection.

The combined use of chemotherapy (CT) and radiotherapy (RT) is becoming increasingly common in the treatment of surgical resected low-grade gliomas (LGGs). However, whether RT or CT is associated with improved overall survival (OS) for low-grade gliomas without surgical resection is less clear.

Stereotactic Cryodestruction of Gliomas.

Surgical resection of gliomas affecting functionally important brain structures is associated with high risk of permanent postoperative neurological deficit and deterioration of the patient's quality of life. The availability of modern neuroimaging and neuronavigation permits the application of minimally invasive stereotactic cryodestruction of the tumor in such cases. The authors used this treatment in 88 patients with supratentorial gliomas of various WHO histopathological grades not suitable for microsur...

Comprehensive evaluation of treatment and outcomes of low-grade diffuse gliomas.

Low-grade gliomas affect younger adults and carry a favorable prognosis. They include a variety of biological features affecting clinical behavior and treatment. Having no guidelines on treatment established, we aim to describe clinical and treatment patterns of low-grade gliomas across the largest cancer database in the United States.

Gene Therapy and Virotherapy of Gliomas.

Despite many recent advances in the management of gliomas, such as aggressive surgical resection, chemoradiotherapy, antiangiogenic therapy, and molecular targeted therapy, the survival of patients with high-grade neoplasms remains dismal. Gene therapy and oncolytic virotherapy have emerged as highly promising strategies for treatment of malignant brain tumors due to recent progress in understanding of the underlying cancer biology as well as improved techniques for genetic modification of potential therape...

Genetic and epigenetic contribution to astrocytic gliomas pathogenesis.

Astrocytic gliomas are the most common and lethal form of intracranial tumors. These tumors are characterized by a significant heterogeneity in terms of cytopathological, transcriptional and (epi)genomic features. This heterogeneity has made these cancers one of the most challenging types of cancers to study and treat. To uncover these complexities and to have better understanding of the disease initiation and progression, identification and characterization of underlying cellular and molecular pathways re...

Demethylation and epigenetic modification with 5-Azacytidine reduces IDH1 mutant glioma growth in combination with Temozolomide.

Isocitrate Deyhydrogenase (IDH) mutant gliomas are comprised of the majority of grade II-III gliomas and nearly all secondary glioblastomas. These progressive gliomas arise from mutations in IDH1 or IDH2 that pathologically produces D-2-hydroxyglutarate (2HG). 2-HG interferes with cell reactions using alpha ketoglutarate leading to a hypermethylated genome and epigenetic dysregulation of gene expression initiating tumorigenesis.

New perspectives in fire management in South American savannas: The importance of intercultural governance.

Wildfires continue to cause damage to property, livelihoods and environments around the world. Acknowledging that dealing with wildfires has to go beyond fire-fighting, governments in countries with fire-prone ecosystems have begun to recognize the multiple perspectives of landscape burning and the need to engage with local communities and their practices. In this perspective, we outline the experiences of Brazil and Venezuela, two countries where fire management has been highly contested, but where there h...

Brain T1ρ mapping for grading and IDH1 gene mutation detection of gliomas: a preliminary study.

The longitudinal relaxation time in the rotating frame (T1ρ) has proved to be sensitive to metabolism and useful in application to neurodegenerative diseases. However, few literature exists on its utility in gliomas. Thus, this study was conducted to explore the performance of T1ρ mapping in tumor grading and characterization of isocitrate dehydrogenase 1 (IDH1) gene mutation status of gliomas.

Management of Intraductal Papillary Mucinous Neoplasms: Controversies in Guidelines and Future Perspectives.

Management of intraductal papillary mucinous neoplasm (IPMN) is currently based on consensus, in the absence of evidence-based guidelines. In recent years, several consensus guidelines have been published, with distinct management strategies. In this review, we will discuss these discrepancies, in order to guide treating physicians in clinical management.

Role of diffusional kurtosis imaging in grading of brain gliomas: a protocol for systematic review and meta-analysis.

Central nervous system (CNS) gliomas are the most common primary intra-axial brain tumours and pose variable treatment response according to their grade, therefore, precise staging is mandatory. Histopathological analysis of surgical tumour samples is still deemed as the state-of-the-art staging technique for gliomas due to the moderate specificity of the available non-invasive imaging modalities. A recently evolved analysis of the tissue water diffusion properties, known as diffusional kurtosis imaging (DK...

An evidence-based approach to assess the accuracy of diffusion kurtosis imaging in characterization of gliomas.

Accurate and noninvasive pathologic grading of glioma patients before surgery was crucial to guiding clinicians to select appropriate treatment and improve patient prognosis. This study was performed to investigate the potential diagnostic value of diffusion kurtosis imaging (DKI) to distinguish high-grade gliomas (HGGs) from low-grade gliomas (LGGs) based on an evidence-based approach.

Methylation-mediated miR-155-FAM133A axis contributes to the attenuated invasion and migration of IDH mutant gliomas.

Gliomas with isocitrate dehydrogenases genes mutation (IDH) were found to be less aggressive than their wildtype (IDH) counterparts. However, the mechanism remains unclear. The current study aims to investigate the role of silenced oncogenic microRNAs in IDH gliomas, which were largely ignored and may contribute to the less aggressive behavior of IDH gliomas. Microarrays, bioinformatics analysis of the data from TCGA and qPCR analysis of samples from our experimental cohort (LGG: IDH=10, IDH=31; GBM: IDH=34...

Updates in prognostic markers for gliomas.

Gliomas are the most common primary malignant brain tumor in adults. The traditional classification of gliomas has been based on histologic features and tumor grade. The advent of sophisticated molecular diagnostic techniques has led to a deeper understanding of genomic drivers implicated in gliomagenesis, some of which have important prognostic implications. These advances have led to an extensive revision of the World Health Organization classification of diffuse gliomas to include molecular markers such ...

How patients with gout become engaged in disease management: a constructivist grounded theory study.

Prior qualitative research on gout has focused primarily on barriers to disease management. Our objective was to use patients' perspectives to construct an explanatory framework to understand how patients become engaged in the management of their gout.

Correction to: SEOM clinical guidelines for anaplastic gliomas (2017).

The SEOM/GEINO clinical guidelines provide recommendations for radiological, and molecular diagnosis, treatment and follow-up of adult patients with anaplastic gliomas (AG). We followed the 2016 WHO classification which specifies the major diagnostic/prognostic and predictive value of IDH1/IDH2 missense mutations and 1p/19q codeletions in AG. The diagnosis of anaplastic oligoastrocytoma is discouraged. Surgery, radiotherapy and chemotherapy with PCV or TMZ are the first-line standard of care for AG with sli...

Quick Search